Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc is a global medical technology company that designs, manufactures and markets advanced medical devices for use in orthopaedic reconstruction, endoscopic procedures and wound management. The company’s innovations span joint replacement systems, minimally invasive surgical tools and advanced wound care products, serving surgeons, hospitals and outpatient facilities worldwide.

Across its Orthopaedics segment, Smith & Nephew offers hip and knee arthroplasty systems, trauma fixation devices and sports medicine solutions for ligament repair and soft tissue reconstruction. Its Endoscopy division provides fluid management platforms, arthroscopic and laparoscopic instruments, as well as diagnostic and therapeutic endoscopy products. In Advanced Wound Management, the company markets negative pressure wound therapy systems, compression garments and a portfolio of alginate, foam and antimicrobial dressings.

Founded in Hull, England in 1856 by Thomas James Smith, the firm adopted the Smith & Nephew name when his nephew Horatio Nelson Smith joined in 1896. Over more than a century of development, the company has expanded its R&D footprint across Europe, North America and Asia, establishing manufacturing sites and innovation centers focused on digital surgery and tissue regeneration. Today, Chief Executive Officer Roland Diggelmann leads a senior management team committed to advancing patient outcomes through minimally invasive and tissue-preserving interventions.

Smith & Nephew’s products are distributed in more than 100 countries, with regional headquarters in the Americas, Europe, Asia Pacific and the Middle East & Africa. The company collaborates with healthcare providers, research institutions and professional societies to support clinical education and drive adoption of its technologies in hospital networks, ambulatory surgical centers and specialized wound clinics around the globe.

Key Stats

• Today's Range: $30.05 to $30.76
• 50-Day Range: $28.00 to $30.67
• 52-Week Range: $23.69 to $31.72
• Volume: 3.96 million shs
• Average Volume: 820,430 shs
• Market Capitalization: $13.46 billion
• P/E Ratio: 14.23
• Dividend Yield: 2.90%
• Price Target: $28.00
• Consensus Rating: Hold

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 72% of companies evaluated by MarketBeat, and ranked 374th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Smith & Nephew SNATS has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 18.34%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Smith & Nephew SNATS is 14.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Smith & Nephew SNATS is 14.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 0.92. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.57% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 2.99%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.57% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.85

News Sentiment

Smith & Nephew SNATS has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Smith & Nephew SNATS this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

Only 25.64% of the stock of Smith & Nephew SNATS is held by institutions.

SNN Stock Analysis - Frequently Asked Questions

How have SNN shares performed this year?

Smith & Nephew SNATS's stock was trading at $24.58 at the beginning of 2025. Since then, SNN shares have increased by 25.1% and is now trading at $30.74.

How were Smith & Nephew SNATS's earnings last quarter?

Smith & Nephew SNATS, Inc. (NYSE:SNN) released its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.59.

Who are Smith & Nephew SNATS's major shareholders?

Smith & Nephew SNATS's top institutional shareholders include Gallacher Capital Management LLC, Marotta Asset Management and Parallel Advisors LLC.

How do I buy shares of Smith & Nephew SNATS?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Smith & Nephew SNATS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/17/2014
• Record date for 5/28 Dividend: 3/28/2025
• Ex-Dividend for 5/28 Dividend: 3/28/2025
• Dividend Payable: 5/28/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 17,349
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: -5.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 13.77
• Forward P/E Ratio: 17.60
• P/E Growth: 0.92
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.89
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $5.81 billion
• Price / Sales: 2.24
• Cash Flow: $3.13 per share
• Price / Cash Flow: 9.49
• Book Value: $12.04 per share
• Price / Book: 2.47

Miscellaneous

• Outstanding Shares: 437,970,000
• Free Float: 433,593,000
• Market Cap: $13.03 billion
• Optionable: Optionable
• Beta: 0.69